Health Care

Intuitive Surgical’s latest quarter shows 19% revenue growth and 16% profit boost, yet its high 58× P/E sparks debate as analysts split on future value.

Tonix Pharmaceuticals: pioneering CNS disorder therapies for fibromyalgia and PTSD, growing R&D pipeline and investor resilience despite market volatility.

Discover how Kuros Biosciences AG, a Swiss biotech leader, innovates orthobiologics to repair bone defects and advance regenerative spinal therapies worldwide.

New securities‑fraud lawsuit hits San Francisco‑based Nektar Therapeutics, probing its drug‑development claims and financial woes while investors weigh the fallout.

Orthocell Ltd’s biotech focus on tendon & ligament repair faces major financial risks, with a negative P/E and falling stock—investors must weigh innovation against profitability.

Amplia Therapeutics: Melbourne‑based biotech innovating immuno‑oncology drugs to fight cancer—high‑risk, high‑reward investments with global impact.

Virax Biolabs’ new private placement injects capital into a biotech firm focused on viral diagnostics, PPE, and immunology—boosting shares and positioning it for growth in the healthcare sector.

Equillium Inc. earns a “Strong Buy” from Raymond James, boosting investor confidence as its autoimmune pipeline shows promise and may lift stock prices.

Vanda Pharmaceuticals faces a tough road: negative earnings, a steep stock drop, and a -1.96 P/E ratio, yet its CNS‑focused drugs keep investors on edge for breakthrough therapies.

Biomerica’s innovative focus on early chronic disease diagnostics, orthodontic gear, and allergy treatments promises better patient outcomes and lower health costs—yet investors watch its financial hurdles.